Recce Ltd (ASX:RCE) has achieved anti-viral activity against influenza virus during in-vitro testing of its lead drug RECCE 327.
Recce specialises in the development of antibiotics and anti-cancer drugs that fights against bacteria, including superbugs, even after repeated use.
The test data suggests that RECCE 327 may be used to target Influenza A virus (H1N1) located external to cells and thus preventing the virus from spreading.
Significantly, the test shows that there is a direct, linear relationship between concentration of RECCE 327, and inhibition of the virus.
The company has lodged a patent application to include the above data and will continue the preliminary assessment of RECCE’s anti-viral capabilities through a projected in-vivo test.
These results, although early stage for RECCE® 327 with in-vitro tests, are encouraging against influenza, but also for its wider anti-cancer properties.
Recce has granted patents in Australia, United States, Europe, Japan and China.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.